Copper in Alzheimer's disease: too much or too little?

Joseph F. Quinn, Susanne Crane, Christopher Harris, Teri L. Wadsworth

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


A considerable amount of literature has accrued examining the role of copper in the pathogenesis of Alzheimer's disease. Remarkably, there is in vitro and animal data to support both copper toxicity and copper deficiency as relevant mechanisms in Alzheimer's disease. These data have prompted preliminary clinical trials of both copper complexing therAβy and copper supplementation therAβy, which have yielded mixed results. The preclinical and clinical studies are discussed here in an effort to determine how to move forward with rational clinical trials focused on copper modulation.

Original languageEnglish (US)
Pages (from-to)631-637
Number of pages7
JournalExpert Review of Neurotherapeutics
Issue number5
StatePublished - May 2009


  • Alzheimer's disease
  • Animal model
  • Chelation
  • Clinical trial
  • Copper
  • Oxidative damage

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Copper in Alzheimer's disease: too much or too little?'. Together they form a unique fingerprint.

Cite this